Venus Remedies Limited

VENUSREM.BO

VENUSREM.BOVenus Remedies Limited IN flag

Bombay Stock Exchange

290.75

INR

-1.20

(-0.41%)

26.08EPS

11.15P/E

3.89BMarket Cap

Feb 04Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

INE411B01019

Return %

Stock

S&P500

-10.22

18.57

-23.24

40.07

-23.24

86.07

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	444.81	480.11	476.88	405.02	361.5	345.21	299.38	257.23	274.94	444.11	453.66	413.99	442.47	478.84
Basic EPS, GAAP	51.22	58.8	57.17	4.51	1.48	-14.88	-24.87	-23.16	-8.1	50.04	30.86	19.87	21.31	26.15
Free Cash Flow per Basic Share	45.34	-53.25	-37.37	0.33	-3.12	11.17	25.27	28.69	56.57	106.82	31.15	21.55	17.78	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	95.57	115.47	131.37	133.63	96.94	82.81	52.43	29.33	20.85	70.81	98.05	116.33	137.5	- -
Tangible Book Value per Share	140.38	179.31	209.63	190.03	162.38	170.28	146.93	133.32	176.66	245.96	267.14	285.1	300.99	- -
Basic Weighted Avg Shares	9	10	11	11	11	11	12	12	12	12	13	13	13	13
Sales/Revenue/Turnover	4,088	4,679	5,363	4,635	4,149	3,963	3,695	3,174	3,393	5,481	5,986	5,534	5,914	6,381
Operating Margin (%)	19.12	18.62	17.7	9.36	9.54	2.69	1.53	-0.46	2.6	3.38	4.77	5.01	5.61	4.73
Depreciation Expense	113	331	402	460	416	403	338	340	320	353	335	323	264	237
Net Income, GAAP	471	573	643	52	17	-171	-307	-286	-100	618	407	266	285	349
Effective Tax Rate (%)	7.42	8.8	6.92	- -	51.56	- -	- -	- -	- -	- -	- -	29.96	36.18	40.19
Profit Margin (%)	11.52	12.25	11.99	1.11	0.41	-4.31	-8.31	-9	-2.95	11.27	6.8	4.8	4.82	5.46
Working Capital	151	343	611	704	839	626	299	18	694	1,366	1,853	2,403	2,801	- -
LT Debt	991	1,291	1,400	2,023	1,910	1,618	1,374	1,160	721	468	387	387	387	- -
Total Equity	3,073	3,791	4,616	4,567	3,997	3,887	3,619	3,325	3,234	4,003	4,404	4,603	4,876	- -
Return on Invested Capital (%)	16.97	13.49	12.62	- -	2.54	- -	- -	- -	- -	- -	- -	3.94	4.1	- -
Return on Capital (%)	34.45	22.27	21.35	- -	3.8	- -	- -	- -	- -	- -	- -	14.4	13.5	53.89
Return on Common Equity (%)	97.1	57.2	49.4	3.43	1.29	-16.56	-38.42	-56.64	-32.29	109.2	37.57	18.65	16.79	- -

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	2.76%	15.4%	6.88%
Net Income, GAAP	-203.6%	-168.86%	7.25%
Free Cash Flow	-137.11%	13.96%	-17.5%
Total Cash Common Dividend	- -	- -	- -
Total Equity	1.02%	8.3%	5.91%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Ashutosh Jain B.A., LL.B
Full Time Employees: 1,187
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: Plot 51-52, Industrial Area Panchkula India 134113
IPO Date: Oct 19, 2004
Website: venusremedies.com
Similar Companies: The Cannabist Company Holdings Inc. (CBSTF)
Medicamen Biotech Limited (MEDICAMEQ.BO)
Antisense Therapeutics Limited (ANP.AX)
MultiCorp International, Inc. (MCIC)
Decibel Cannabis Company Inc. (DBCCF)
AlzeCure Pharma AB (publ) (ALZCUR.ST)
Business: Venus Remedies Limited engages in the development and marketing of pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin care, wound management, stress reliever, urology, and vitamins/minerals/nutrients, as well as antimicrobial resistance products. It is also involved in the provision of anti-infective, anticoagulant, and a portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	444.81	480.11	476.88	405.02	361.5	345.21	299.38	257.23	274.94	444.11	453.66	413.99	442.47	478.84
Basic EPS, GAAP	51.22	58.8	57.17	4.51	1.48	-14.88	-24.87	-23.16	-8.1	50.04	30.86	19.87	21.31	26.15
Free Cash Flow per Basic Share	45.34	-53.25	-37.37	0.33	-3.12	11.17	25.27	28.69	56.57	106.82	31.15	21.55	17.78	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	95.57	115.47	131.37	133.63	96.94	82.81	52.43	29.33	20.85	70.81	98.05	116.33	137.5	- -
Tangible Book Value per Share	140.38	179.31	209.63	190.03	162.38	170.28	146.93	133.32	176.66	245.96	267.14	285.1	300.99	- -
Basic Weighted Avg Shares	9	10	11	11	11	11	12	12	12	12	13	13	13	13
Sales/Revenue/Turnover	4,088	4,679	5,363	4,635	4,149	3,963	3,695	3,174	3,393	5,481	5,986	5,534	5,914	6,381
Operating Margin (%)	19.12	18.62	17.7	9.36	9.54	2.69	1.53	-0.46	2.6	3.38	4.77	5.01	5.61	4.73
Depreciation Expense	113	331	402	460	416	403	338	340	320	353	335	323	264	237
Net Income, GAAP	471	573	643	52	17	-171	-307	-286	-100	618	407	266	285	349
Effective Tax Rate (%)	7.42	8.8	6.92	- -	51.56	- -	- -	- -	- -	- -	- -	29.96	36.18	40.19
Profit Margin (%)	11.52	12.25	11.99	1.11	0.41	-4.31	-8.31	-9	-2.95	11.27	6.8	4.8	4.82	5.46
Working Capital	151	343	611	704	839	626	299	18	694	1,366	1,853	2,403	2,801	- -
LT Debt	991	1,291	1,400	2,023	1,910	1,618	1,374	1,160	721	468	387	387	387	- -
Total Equity	3,073	3,791	4,616	4,567	3,997	3,887	3,619	3,325	3,234	4,003	4,404	4,603	4,876	- -
Return on Invested Capital (%)	16.97	13.49	12.62	- -	2.54	- -	- -	- -	- -	- -	- -	3.94	4.1	- -
Return on Capital (%)	34.45	22.27	21.35	- -	3.8	- -	- -	- -	- -	- -	- -	14.4	13.5	53.89
Return on Common Equity (%)	97.1	57.2	49.4	3.43	1.29	-16.56	-38.42	-56.64	-32.29	109.2	37.57	18.65	16.79	- -

Year	Q1	Q2	Q3	Q4	FY
2023	1,431	1,399	1,169	1,535	5,534
2024	952	1,677	1,434	1,852	5,914
2025	1,086	1,674	1,769	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	5.16	3.99	2.46	- -	19.87
2024	0.88	7.44	5.13	- -	21.31
2025	0.92	2.63	14.66	- -	- -

	Jun'25	Sep'25	Dec'25
Total Current Assets	- -	3,915	- -
Accounts Receivable, Net	- -	677	- -
Cash, Cash Equivalents & STI	- -	1,349	- -
Inventories	- -	1,200	- -
Total Current Liabilities	- -	1,010	- -
Payables & Accruals	- -	- -	- -
ST Debt	- -	22	- -
Deferred Revenue	- -	- -	- -

	Jun'25	Sep'25	Dec'25
ST Debt	- -	22	- -
LT Borrowings	- -	387	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	- -	13	- -
Market Capitalization	4,778	4,496	4,266

Venus Remedies Limited

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year